Abstract: Provided herein are antibodies and methods of use thereof. The antibodies as disclosed herein bind to CD163+ on cells, such as on macrophages. These antibodies can be used in methods of treatment, such as methods of treating cancer.

Abstract: Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin administration for patients suffering headache, particularly chronic migraine.

Abstract: The present invention relates to a fusion protein comprising an extracellular domain of leucine-rich and immunoglobulin-like domains-1 (Lrig-1) protein and an immunoglobulin Fc region. The fusion protein provided in the present invention can interact with a ligand for Lrig-1 protein, which is present on effector T cells, to inhibit the interaction between the effector T cells and regulatory T cells (Treg cells) having the Lrig-1 protein on their surface, so that activity of the regulatory T cells is inhibited and activity of the effector T cells is maintained or elevated, thereby effectively inhibiting growth of cancer cells, in particular, solid cancer cells.

Abstract: The present disclosure provides an antibody that binds human Adhesion G Protein-Coupled Receptor B1 (BAI1) protein, compositions comprising the same, and use thereof in methods of detection, methods of diagnosis, and methods of treatment.

Abstract: The present disclosure provides ?2?-1 C-terminal domain mimetics for the treatment of pain, epilepsy or other disorders in a subject. Further provided is an ?2?-1 C-terminal domain peptide which blocks binding of ?2?-1 to the glutamate receptors NMDAR and AMPAR.

Abstract: Modified relaxin polypeptides and their uses thereof are provided. Exemplary embodiments provide relaxin polypeptides which include one or more amino acid substitutions with natural or non-naturally encoded amino acids, and/or linkage to a water-soluble polymer, such as polyethylene glycol. Additionally, use of said relaxin polypeptides for treatment of disease, such as heart failure, is also provided.

Abstract: Insulin-like growth factor-binding protein 3 receptor (IGFBP-3R) agonists and methods of their use to treat diseases involving IGFBP-3 and IGFBP-3R are provided. The agonists may be antibodies or other molecules specific for binding to and activating IGFBP-3R. The agonists are used to treat e.g. cancer, metabolic syndrome and obstructive respiratory disorders. In addition, methods of diagnosing cancer and predicting the chance of recurrence, metastasis and/or survival by measuring the level of IGFBP-3R in tumor tissue are provided.

Abstract: The present invention relates to monoclonal antibodies that specifically bind to human pituitary adenylate cyclase activating polypeptide (PACAP) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the monoclonal antibodies are also described.

Abstract: Provided herein are a gastric inhibitory polypeptide receptor (GIPR) antibody and its fusion protein with glucagon-like peptide-1 (GLP-1), and a pharmaceutical composition thereof. Also provided herein is a method for using the GIPR antibody and its fusion protein with GLP-1 to treat, prevent or improve one or more symptoms of non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, type 2 diabetes or obesity.

Abstract: The present invention provides compositions and methods for treating tumor-induced osteomalacia. The method entails administering to a subject a pharmaceutical composition containing an anti-FGF23 ligand, wherein the dosing regimen of the pharmaceutical is designed to reach effective and efficient control of FGF23 activity.

Abstract: Antibody antigen binding domains which specifically binds human leptin comprises VH or VL CDR1, CDR2 and CDR3 sequences of an hLept antibody. The antibody antigen binding domains and antibodies thereof are useful to treat obesity and diabetes.

Abstract: The present application relates to compositions comprising fusion proteins and cells expressing the proteins. The application further relates to methods of using the fusion proteins, cells, and compositions for modulating cell signaling and for selective expansion of cells.

Abstract: The present disclosure relates to a human FGF21 mutant with improved effectiveness and stability, preparation method and pharmaceutical composition comprising the mutant, and a use thereof, and specifically relates to a human fibroblast growth factor 21 (FGF21) mutant, a gene encoding the same, and a method for preparing the mutant and a method of using the mutant for treating type 2 diabetes, obesity, dyslipidemia, or metabolic disorders.

Abstract: Various aspects of the invention relate to recombinant polypeptides that specifically bind human von Willebrand Factor. Such recombinant polypeptides typically include a modified extracellular domain of platelet glycoprotein Ib? that typically comprises at least one mutation selected from G233T, D235V, and K237V, and such recombinant polypeptides optionally include an oligomerization domain.

Abstract: The present invention relates to a pharmaceutical composition comprising, as an active ingredient, a fusion protein in which a tissue-penetrating peptide is fused to an anti-vascular endothelial growth factor agent, methods of treating eye diseases with the pharmaceutical composition, and a method for preparing an anti-VEGF agent with an improved efficacy and ability to overcome resistance.

Abstract: The present disclosure relates to the field of biotechnology, and more specifically, to single-chain and multi-chain chimeric polypeptides having a linker domain positioned between two target-binding domains that are useful for a variety of applications including, without limitation, stimulating an immune cell, inducing or increasing proliferation of an immune cell, inducing differentiation of an immune cell, or treating a subject in need thereof (e.g., a subject having cancer or an aging-related disease or condition).

Abstract: The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.

Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.

Abstract: The present invention relates to C-X-C motif chemokine ligand 10 (CXCL10) binding proteins and uses thereof in methods of detecting and/or diagnosing a condition in a subject, comprising determining a level of CXCL10 in the subject. Specific antibodies that bind to total CXCL10 (full-length, N-terminally truncated and citrullinated) and antibodies that bind active CXCL10 (full-length) were used to measure the level of total and active CXCL10 in samples from ovarian cancer patients. The calculated ratio of active to total CXCL10 was lower in patients with malignant condition when compared to patients with benign tumours or healthy individuals and is the basis of method of diagnosis of malignant conditions, monitoring tumour burden and disease progression.

Abstract: The present disclosure provides methods of treating an ocular disease or disorder. The methods involve direct administration into the eye of a conjugate comprising a biologically active polypeptide and a biocompatible polymer.